Compare DexCom, Inc. (DXCM) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Synopsys, Inc. — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while Synopsys, Inc. trades at $419.99 (market cap $81.43B). The key difference: Synopsys, Inc. is far larger — about 2.9× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | SNPS | |
|---|---|---|
Market Cap | $28.06B | $81.43B |
Sector | Health | Technology |
52-Week High | $89.53 | $645.59 |
52-Week Low | $54.84 | $380.47 |
Enterprise Value | $27.03B | $89.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Synopsys (SNPS) trades at $425.81, down 1.85% amid bearish technical signals, though it maintains strong analyst support with 82.8% buy ratings and a $559.50 consensus target. The company shows consistent earnings beats and robust revenue growth to $7.05B in 2025, though profitability metrics like net margin (8.91%) and ROE (3.83%) are tempered by high valuations (P/E 97.32). Recent news highlights its strategic pivot to AI-driven design tools and the integration of Ansys, positioning it as a key enabler in the semiconductor ecosystem.
The outlook remains positive given SNPS's strategic positioning in AI and semiconductor design, with significant upside to analyst targets. Risks include execution challenges from the Ansys integration, competitive pressures, and sensitivity to semiconductor cycles. Investors should weigh high valuation multiples against growth potential in the expanding AI market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
